Search

ACADIA Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

29 3.02

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.1

Максимум

29

Ключови измерители

By Trading Economics

Приходи

32M

35M

Продажби

40M

308M

P/E

Средно за сектора

13.121

57.002

EPS

0.18

Марж на печалбата

11.41

Служители

796

EBITDA

25M

32M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+21.58% upside

Дивиденти

By Acuity

Следващи печалби

4.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

647M

5B

Предишно отваряне

25.98

Предишно затваряне

29

Настроения в новините

By Acuity

50%

50%

154 / 340 Класиране в Healthcare

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.08.2026 г., 23:06 ч. UTC

ACADIA Pharmaceuticals shares are trading higher in after-market hours, maintaining a gain while above their 20-day moving average and near a one-month high.

13.08.2026 г., 20:01 ч. UTC

ACADIA Pharmaceuticals Inc shares are lower today, continuing a decline from Wednesday's close. No specific news was identified to explain the movement.

12.08.2026 г., 19:56 ч. UTC

News

Needham maintained its Buy rating on ACADIA Pharmaceuticals and raised the price target to $41. Shares are trading higher since Tuesday's close.

11.08.2026 г., 19:36 ч. UTC

ACADIA Pharmaceuticals remains near unchanged amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports affecting interest rate policy.

7.08.2026 г., 20:06 ч. UTC

ACADIA Pharmaceuticals Inc shares are advancing, maintaining a strong position above the 20-day moving average and near the upper end of their one-month range.

6.08.2026 г., 23:41 ч. UTC

ACADIA Pharmaceuticals shares are higher in after-market trading, reflecting strong performance above its 20-day moving average and nearing the upper end of its one-month range.

5.08.2026 г., 20:02 ч. UTC

News

ACADIA Pharmaceuticals shares rise following strong Q2 results and positive analyst ratings, with revenue guidance increased to $1.24 billion to $1.30 billion.

4.08.2026 г., 23:01 ч. UTC

News

Acadia Pharmaceuticals shares are higher after reporting strong Q2 results, with GAAP net sales of DAYBUE reaching $125 million and raising full-year revenue guidance.

3.08.2026 г., 21:01 ч. UTC

ACADIA Pharmaceuticals Inc shares are lower in after-market trading, continuing a trend of three consecutive sessions finishing lower without any specific news identified.

31.07.2026 г., 20:03 ч. UTC

ACADIA Pharmaceuticals shares are lower today, continuing a decline since Thursday's close. Rising Treasury yields and crude oil prices contribute to inflation concerns.

30.07.2026 г., 19:58 ч. UTC

ACADIA Pharmaceuticals shares are higher, reflecting a broader recovery in tech stocks amid improving market sentiment and bargain hunting after recent sell-offs.

29.07.2026 г., 20:41 ч. UTC

ACADIA Pharmaceuticals shares are lower in after-market trading amid a broader market decline linked to rising crude oil prices and geopolitical tensions.

28.07.2026 г., 20:06 ч. UTC

ACADIA Pharmaceuticals is rising amid strong performance in the Biotechnology sector. The stock is nearing the upper end of its one-month range.

27.07.2026 г., 20:01 ч. UTC

ACADIA Pharmaceuticals Inc. shares are higher today, continuing an upward trend since Friday's close, despite no specific news driving the price movement.

24.07.2026 г., 19:56 ч. UTC

ACADIA Pharmaceuticals shares are higher since Thursday's close, despite a dip earlier in the session. The stock remains below its 20-day moving average.

23.07.2026 г., 10:06 ч. UTC

ACADIA Pharmaceuticals is trading higher in pre-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

22.07.2026 г., 22:16 ч. UTC

ACADIA Pharmaceuticals shares are lower in after-market trading, with unusual activity noted. Broader market concerns may be influencing investor sentiment.

21.07.2026 г., 23:16 ч. UTC

ACADIA Pharmaceuticals Inc. shares traded roughly flat in after-market hours, remaining near the upper end of their one-month trading range.

20.07.2026 г., 19:56 ч. UTC

Event
News
Social Media

Acadia Pharmaceuticals received Fast Track designation for remlifanserin, but shares are lower today, continuing a trend of declines over the past three sessions.

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

21.58% нагоре

12-месечна прогноза

Среден 35.27 USD  21.58%

Висок 49 USD

Нисък 25 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

12

Купи

4

Задържане

0

Продай

Настроение

By Acuity

154 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat